Detalhe da pesquisa
1.
Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type.
Ann Allergy Asthma Immunol
; 132(3): 383-389.e3, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37949351
2.
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Am J Clin Dermatol
; 24(1): 97-107, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512175